Drug Approval | March 01, 2024
Biocon Biologics secures US market entry date for Bmab 1200
The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA
The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA
The U.S. FDA recently approved Xolair as the first and only medicine for children and adults with one or more food allergies
The acquisition of Healint aligns with Aptar Digital Health’s strategy to broaden its portfolio in neurology and strengthen its global footprint for digital health deployment
He is a former Neurology faculty member at The Johns Hopkins Hospital and an elected Fellow of the Royal College of Physicians, United Kingdom
Approval based on a separate phase III trial among Chinese patients reinforcing mepolizumab’s efficacy and safety data
The transfer of the distribution rights will strengthen Sandoz's immunology and biosimilar portfolio
The Regional Reference Laboratory in Chennai is equipped with cutting-edge diagnostic technologies
The full transition of Viatris' biosimilars operations to Biocon Biologics in Europe represents another significant milestone
Accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
Total transaction value of the divestment is Rs. 3,660 million
Subscribe To Our Newsletter & Stay Updated
